Nazli Dizman, MD, Yale University School of Medicine, New Haven, CT, talks on the association of the gut microbiome with response to immunotherapies and modulating the gut microbiome to improve...

Justin Roe, BA(Hons), Dip THP, PG Dip, MSc, PhD, FRCSLT, of the Royal Marsden NHS Foundation Trust, London, UK, discusses the management of swallowing, speech and voice problems resulting from head...

Aleix Prat, MD, PhD, Clinical and Provincial Hospital of Barcelona, Barcelona, Spain, discusses a meta-analysis that validated the association of the HER2-E subtype with pathological complete...

In many solid tumor cancers, there are a high number of mutations which are beneficial for immune therapy. Furthermore, large numbers of infiltrating T-cells are considered beneficial. David A....

Here, Celia Diez de los Rios, ANP, from the University of Southampton NHS Foundation Trust, Southampton, UK, discusses the impact of novel cancer therapies on the role of nurses. Speaking at the...

Adrienne Waks, MD, Dana-Farber Cancer Center, Boston, MA, discusses the evaluation of the HER2DX test's predictive value in neoadjuvant therapy for HER2-positive breast cancer. The study aimed to...

Rachna Shroff, MD, MS, University of Arizona College of Medicine, Tucson, AZ, discusses the latest developments in the targeted therapies for biliary tract cancers, including encouraging findings...

Evandro de Azambuja, MD, PhD, of the Institut Jules Bordet, Brussels, Belgium, discusses how data from the MONARCH study (NCT02107703) is introducing chemotherapy-free treatment for patients with...

Elisa Agostinetto, MD, Istituto Clinico Humanitas, Rozzano, Milan, Italy, discusses ROSALINE (NCT04551495), a Phase II trial-in-progress neoadjuvant study of targeting ROS1 in combination with...

Aleix Prat, MD, PhD, Clinical and Provincial Hospital of Barcelona, Barcelona, Spain, discussed the phenotypic changes of HER2+ breast cancer during and after dual HER2 blockade. This interview was...

Aleix Prat, MD, PhD, Clinical and Provincial Hospital of Barcelona, Barcelona, Spain, discusses the CORALLEEN trial (NCT03248427), which investigated neadjuvant multi-agent chemotherapy or letrozole...

Vidit Sharma, MD, MS, Mayo Clinic, Rochester, MN, discusses the financial impact of bladder cancer and the impact of cost on the quality of life of a patient. The cost of bladder tends to be diseas...

Matteo Lambertini, MD, PhD, IRCCS AOU San Martino (Ospedale Policlinico San Martino), Genova, Italy, discusses the recently published ESMO Clinical Practice Guidelines in fertility preservation and...

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, provides an update on the pivotal HER2CLIMB, evaluating tucatinib vs placebo in combination with trastuzumab and capecitabine for...

Matteo Lambertini, MD, PhD, IRCCS AOU San Martino (Ospedale Policlinico San Martino), Genova, Italy, provides a round-up of key presentations from the SABCS 2020 virtual meeting, including results...

Chimeric antigen receptor (CAR) T-cell approaches have led to remarkable advances in the treatment of patients with hematologically malignancies but not yet within solid tumors. In this interview,...

Andreas Charalambous, BSc, MSc, PGCert, PhD, The Cyprus University of Technology, Limassol, Cyprus, outlines the development of the cancer nursing workforce, including technological developments and...

Alastair Greystoke, MBChB, MSc, PhD, MRCP, Northern Institute for Cancer Research, Newcastle University, Newcastle, UK, outlines the need for occupational therapists during early clinical trials in...

Sapna Patel, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on unmet needs in uveal melanoma, including the lack of treatment options for patients with HLA-A*02:01-neg...

Maria Alice Franzoi, MD, Gustave Roussy, Villejuif, France, discusses sexual concerns from survivors of breast cancer (BC) and how these concerns are negatively impacting quality of life. Patient...

Identifying patients who are likely to respond to a specific therapy by biomarkers is useful when it comes to treatment selection. Petros Grivas, MD, PhD, of the Seattle Cancer Care Alliance,...

Matteo Lambertini, MD, PhD, IRCCS Ospedale Policlinico San Martino, Genova, Italy, reports updates from key breast cancer trials presented at ESMO 2021. Firstly, the randomized phase III DESTINY-Br...

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an update on the AMEERA-3 (NCT04059484), ongoing Phase II study of SAR439859, an oral selective estrogen receptor degrader...

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the importance of tailoring medicine in the treatment of early breast cancer, and cites the results of the KATHERINE...

Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, discusses progress in biliary tract cancers and touches on key areas of unmet need, such as improving chemotherapy regimens in...

The past several years have been extremely exciting in the field of bladder cancer, with checkpoint inhibitors emerging as efficacious therapies for otherwise refractory cancer. In this interview,...

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the ALTA-1L study (NCT02737501) which compares the efficacy and safety of brigatinib to that of...

Life can be tough when you are living with cancer or even after treatment ends. Gemma Pearce, PhD, from Coventry University, Coventry, UK, stresses the need for further improvements in patient...

Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the field of theranostics and the latest developments in prostate cancer research. Prof....

Nazli Dizman, MD, Yale University School of Medicine, New Haven, CT, discusses the results of study characterizing the microbial resistome in a prospective trial of CBM588, a live bacterial product,...

Joanne Edwards, PhD, University of Glasgow, Glasgow, UK, talks about subtyping of colorectal cancer using a histology based approach. Recorded at the 2019 National Cancer Research Institute (NCRI)...

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, outlines the first national study investigating the efficacy and outcomes of molecular testing in patients with...

Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses overall survival (OS) data from the Phase III IMvigor130 study (NCT02807636) of atezolizumab plus platinum/gemcitabine...

Icro Meattini, MD, University of Florence, Florence, Italy, provides an update on the ongoing EUROPA trial (NCT04134598), a randomized trial focused on older adults with breast cancer. In this study,...

Evandro de Azambuja, MD, PhD, of the Institut Jules Bordet, Brussels, Belgium, reports small decreases in PFS for obese patients treated with CDK4/6 inhibitors and endocrine therapy in the MONARCH 1...

Shankar Siva, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, explains how radiotherapy can be used in the management of oligometastatic kidney cancer. Strategies include using stereotactic...

Eric K. Singhi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the rationale and results from a retrospective study investigating the safety and clinical outcomes of...

Yara Abdou, MD, University of North Carolina, Chapel Hill, NC, discusses racial differences in the breast tumor microenvironent, highlighting differences in tumor biology that may result in differe...

Enrique Grande, MD, PhD, MSc, MD Anderson Cancer Center Madrid, Madrid, Spain, provides an overview of his highlights presented at the European Society for Medical Oncology (ESMO) 2022 Congress in...

Shankar Siva, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, explains how radiotherapy can be used in the management of oligometastatic kidney cancer. Strategies include using stereotactic...

As chimeric antigen receptor (CAR) T-cell therapies are patient-specific, this novel treatment type poses unique challenges. From the British Oncology Pharmacy Association (BOPA) Annual Symposium...

Bruno Sangro, MD, PhD, of Clinica Universidad de Navarra, Navarra, Spain, discusses results from the Phase III EMERALD-1 study (NCT03778957) which aimed to characterize transarterial chemoembolizat...

David Chang, MBBS, FRACS, PhD, University of Glasgow, Glasgow, UK, outlines the PRECISION-Panc project, designed to bring together key stakeholders in the treatment of pancreatic cancer in the UK, at...

Deborah Mukherji, MBBS, FRCP, American University of Beirut Medical Center, Beirut, Lebanon discusses highlights for colorectal cancer presented during Session IX of the ESMO World Congress on...

Matthew Fowler, BScN, MSc, Heart of England NHS Foundation Trust, Birmingham, UK, discusses the benefits of the introduction of a nurse-led Totally Implantable Vascular Access Device (TIVAD) service...

Dean Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, gives an overview of the Phase II MiST trial (NCT03654833) investigating stratified therapy for the treatment of...

Donald Harvey, PharmD, BCOP, FCCP, FHOPA, from the Winship Cancer Institute, Atlanta, GA, discusses the importance of biomarkers in immunotherapy to improve the identification of good and poor...

Victoria Fashina of Guy’s and St. Thomas’ NHS Foundation Trust, London, UK, discusses the development and aims of the national systemic anti-cancer therapy (SACT) regimen-specific consent forms at...

Daniel Kelly, FRCN, RN, PhD, FRSA, Cardiff University, Cardiff, UK, stresses the importance of ensuring patient safety, with a focus on the human papillomavirus (HPV) vaccination to prevent cervical...

Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, discusses results of a study evaluating circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive,...

Guilherme Nader Marta, MD, Institut Jules Bordet, Brussels, Belgium, provides an overview of the PRISMA study, which examines the feasibility of radioligand therapy in patients with metastatic triple...

Laurence Albiges, MD, PhD, from the Gustave Roussy Institute, Villejuif, France discusses the safety of cabozantinib treatment in metastatic renal cell carcinoma at the European Cancer Congress of...

Aleix Prat, MD, PhD, Clinical and Provincial Hospital of Barcelona, Barcelona, Spain, outlined his talk at ESMO Breast 2020 titled 'Beyond HER2: Dissecting tumor heterogeneity'. Specifically discus...